

Special Issue

Antimicrobial Resistance in Clinical Infection and Antibiotic Stewardship

Message from the Guest Editor

Antimicrobial resistance represents a pressing public health concern. Robust antimicrobial stewardship programs are employed as a method of mitigating the further development of antimicrobial resistance. While there has been an influx of recent literature concerning antimicrobial resistance as a consequence of inappropriate antimicrobial utilization, there remains a need for evidence supporting innovative antimicrobial stewardship initiatives and their correlation with the prevention of antimicrobial resistance. This Special Issue aims to provide a comprehensive update on novel or adapted antimicrobial stewardship initiatives and the relative impact seen on antimicrobial resistance. Manuscripts reporting antimicrobial resistance rates and correlations with antimicrobial utilization, as well as those describing antimicrobial stewardship program development, initiatives, and outcomes, will be considered for publication. We welcome original research articles, reviews, or meta-analyses geared at addressing the aforementioned considerations. I hope you will consider submitting your work to this Special Issue of *Antibiotics*.

Guest Editor

Dr. Daniel T. Anderson
Department of Pharmacology & Toxicology, Medical College of Georgia, Augusta, GA 30912, USA

Deadline for manuscript submissions

closed (31 October 2025)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/179720

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)